Inhibikase Therapeutics
IKT
19 hedge funds and large institutions have $719K invested in Inhibikase Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
1.07% less ownership
Funds ownership: 2.02% → 0.95% (-1.1%)
21% less funds holding
Funds holding: 24 → 19 (-5)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
74% less capital invested
Capital invested by funds: $2.78M → $719K (-$2.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$33.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.3K |
| 3 |
CWM
CCG Wealth Management
San Diego,
California
|
+$6.61K |
| 4 |
SI
Sprott Inc
Toronto,
Ontario, Canada
|
+$6.61K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$394K |
| 2 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$151K |
| 3 |
Renaissance Technologies
New York
|
-$48K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 5 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$17K |
IKT Hedge Fund Activity: Q4 2022 in Review
19 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2022, worth a combined $719K — down 74% from $2.78M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IKT and 3 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was William Blair & Company, adding an estimated $33.1K. The largest seller was Fidelity Investments, exiting entirely with an estimated $394K sold.
- 19 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2022, down from 24 in Q3 2022.
- Funds reported $719K of Inhibikase Therapeutics stock for Q4 2022, down 74% quarter-over-quarter.
- 3 funds opened new Inhibikase Therapeutics positions in Q4 2022 and 7 closed out, a net change of -4 holders.
- The largest Inhibikase Therapeutics buyer in Q4 2022 was William Blair & Company, an estimated $33.1K added.
- The largest Inhibikase Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $394K sold.
Based on aggregated 13F filings for Q4 2022.